Lininger Linda A, Cullum Malford E, Lyles Mark B, Bienek Diane R
Naval Institute for Dental and Biomedical Research, Great Lakes, 310A B-street, Building 1H, Great Lakes, IL 60088-5259, United States.
Vaccine. 2007 Feb 19;25(9):1619-25. doi: 10.1016/j.vaccine.2006.11.005. Epub 2006 Nov 13.
Using a cross-sectional analysis design, we measured serum anti-protective antigen (PA) concentrations in individuals receiving six or fewer US licensed anthrax vaccinations. Samples were collected from 363 individuals with a mean of 29.6+/-8.42 months after their last vaccination (range 3-57 months). An enzyme-linked immunosorbent assay (ELISA) developed and validated by the Centers for Disease Control and Prevention (CDC) was used to evaluate the range and status of anthrax vaccine-induced serum antibody concentrations. A significant correlation (r=0.73, P< or =0.001) was found to exist between the number of vaccinations received and specific anti-PA immunoglobulin G (IgG) concentrations. We observed two discrete groups comprised of one to three doses (5.9-11.7 microg/ml) and four to six doses (26.2-30.2 microg/ml). These data indicate that anti-PA IgG is present at low but detectable levels after as few as two vaccinations (5.9+/-6.43 microg/ml). These findings may have significance for anthrax vaccine recipients who are unable to complete the primary or full regimen with this licensed product.
采用横断面分析设计,我们测量了接受6剂及以下美国许可的炭疽疫苗接种者的血清抗保护性抗原(PA)浓度。样本来自363名个体,他们在最后一次接种疫苗后的平均时间为29.6±8.42个月(范围为3 - 57个月)。使用疾病控制与预防中心(CDC)开发并验证的酶联免疫吸附测定(ELISA)来评估炭疽疫苗诱导的血清抗体浓度范围和状态。发现接种疫苗的次数与特异性抗PA免疫球蛋白G(IgG)浓度之间存在显著相关性(r = 0.73,P≤0.001)。我们观察到两个离散组,一组接受1至3剂疫苗(5.9 - 11.7微克/毫升),另一组接受4至6剂疫苗(26.2 - 30.2微克/毫升)。这些数据表明,仅接种两剂疫苗后(5.9±6.43微克/毫升),抗PA IgG就以低但可检测的水平存在。这些发现对于无法完成该许可产品的初级或完整接种方案的炭疽疫苗接种者可能具有重要意义。